Get the Stockscreener App
1.30
5.69%
0.07
After Hours:
1.26
-0.04
-3.08%
Citius Pharmaceuticals Inc stock is traded at $1.30, with a volume of 350.65K.
It is up +5.69% in the last 24 hours and up +7.44% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$1.23
Open:
$1.3
24h Volume:
350.65K
Relative Volume:
0.78
Market Cap:
$22.12M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.2178
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
-2.26%
1M Performance:
+7.44%
6M Performance:
+38.30%
1Y Performance:
-85.84%
1-Day Range:
$1.225
$1.30
1-Week Range:
$1.22
$1.52
52-Week Range:
$0.65
$12.84
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.30 | 20.92M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Has Citius Pharmaceuticals Inc. found a price floorRisk Management & Precise Entry and Exit Recommendations - newser.com
Should you wait for a breakout in Citius Pharmaceuticals Inc.July 2025 Patterns & Verified Chart Pattern Trade Signals - newser.com
What earnings revisions data tells us about Citius Pharmaceuticals Inc.Global Markets & Smart Swing Trading Alerts - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock considered safe havenRate Cut & Long-Term Capital Growth Strategies - newser.com
Short interest data insights for Citius Pharmaceuticals Inc.July 2025 Rallies & Long Hold Capital Preservation Plans - newser.com
Forecasting Citius Pharmaceuticals Inc. price range with options dataJobs Report & Weekly Consistent Profit Watchlists - newser.com
Can Citius Pharmaceuticals Inc. (47N0) stock sustain breakout momentumJuly 2025 Snapshot & Target Return Focused Picks - newser.com
How currency fluctuations impact Citius Pharmaceuticals Inc. stockDividend Hike & Consistent Profit Trading Strategies - newser.com
Is Citius Pharmaceuticals Inc. still worth holding after the dipJuly 2025 Retail & Risk Managed Investment Signals - newser.com
Citius in talks over Lymphir access in global markets - The Pharma Letter
Is Citius Pharmaceuticals Inc 47N0 a good long term investmentEarnings Growth Projections & High Return Capital Strategies - earlytimes.in
Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - Stock Titan
Published on: 2025-10-06 05:51:11 - newser.com
How strong dollar benefits Citius Pharmaceuticals Inc. (47N0) stock2025 Pullback Review & Expert Approved Momentum Ideas - newser.com
Will Citius Pharmaceuticals Inc. (47N0) stock sustain bullish trend into 2025July 2025 Intraday Action & High Yield Stock Recommendations - newser.com
Can Citius Pharmaceuticals Inc. stock double in next 5 yearsJuly 2025 Outlook & Comprehensive Market Scan Reports - newser.com
How Citius Pharmaceuticals Inc. (47N0) stock reacts to Fed tighteningTrade Volume Summary & Precise Buy Zone Identification - newser.com
Why Citius Pharmaceuticals Inc. (47N0) stock benefits from AI revolutionTrade Analysis Report & Low Drawdown Trading Strategies - newser.com
Detecting price anomalies in Citius Pharmaceuticals Inc. with AITrade Risk Assessment & Weekly High Momentum Picks - newser.com
Will Citius Pharmaceuticals Inc. (47N0) stock deliver compounding returnsWeekly Profit Report & Expert Curated Trade Setup Alerts - newser.com
Strategies to average down on Citius Pharmaceuticals Inc.July 2025 Market Mood & Reliable Entry Point Alerts - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock a buy before earnings resultsJuly 2025 PreEarnings & Intraday High Probability Alerts - newser.com
How to build a dashboard for Citius Pharmaceuticals Inc. stock2025 Analyst Calls & Real-Time Chart Breakout Alerts - newser.com
How to use a screener to detect Citius Pharmaceuticals Inc. breakoutsForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock undervalued at current priceForecast Cut & Free Technical Pattern Based Buy Signals - newser.com
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):